AVITA Medical, Inc. (RCEL)

Market Cap	343.52M
Revenue (ttm)	25.11M
Net Income (ttm)	-17.79M
Shares Out	25.30M
EPS (ttm)	-0.71
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	86,418
Open	13.52
Previous Close	13.53
Day's Range	13.51 - 13.83
52-Week Range	4.41 - 14.75
Beta	0.97
Analysts	Buy
Price Target	19.28 (+41.97%)
Earnings Date	Feb 23, 2023

About RCEL

AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professional...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Mr. James M. Corbett
• Employees: 116
• Stock Exchange: NASDAQ
• Ticker Symbol: RCEL

Financial Performance

In 2022, AVITA Medical's revenue was 37.64 million, an increase of 8.73% compared to the previous year's 34.62 million. Losses were -26.67 million, 6.06% more than in 2021.

Financial numbers in AUD

Analyst Forecast

According to 11 analysts, the average rating for RCEL stock is "Buy." The 12-month stock price forecast is $19.28, which is an increase of 41.97% from the latest price.

Price Target

$19.28

(41.97% upside)

Analyst Consensus: Buy